3 years of revenue, profit, cash flow and balance-sheet history through FY2026,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 84.9% per year over the past 2 years.
Operating margin has expanded, at -141.6% in the latest year.
Financial health
The company holds more cash ($100M) than total debt ($43M).
Total debt has grown slower than revenue (0.1% vs 84.9% per year).
Operating income covered interest expense -17.9× in the latest year, down from -13.7× 2 years ago.
The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2026
$95M
-$132M
51.4%
-141.6%
-50.7%
-36.7%
-$117M
$43M
$100M
2025
$60M
-$114M
40.5%
-177.8%
-55.4%
-38.5%
-$101M
$41M
$238M
2024
$28M
-$94M
1.3%
-305.8%
45.0%
-204.8%
-$84M
$43M
$8M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Apr '26
$29M
-$39M
54.8%
-137.4%
-15.0%
-10.8%
-$28M
$43M
$100M
Jan '26
$25M
-$34M
52.6%
-141.6%
-11.9%
-9.0%
—
$42M
$291M
Oct '25
$23M
-$33M
50.6%
-140.7%
-20.0%
-13.3%
-$26M
$42M
$175M
Jul '25
$19M
-$26M
45.7%
-149.1%
-14.0%
-9.7%
-$34M
$41M
$201M
Apr '25
$17M
-$52M
44.3%
-279.8%
-25.3%
-17.6%
-$31M
$41M
$238M
Jan '25
$15M
-$22M
43.4%
-136.5%
8.3%
—
—
—
$54M
Oct '24
$15M
-$20M
39.6%
-130.1%
8.6%
—
-$23M
—
$77M
Jul '24
$13M
-$20M
32.9%
-144.2%
9.2%
—
-$25M
—
$100M
Valuation over time
How the market has priced KMTS against its own fundamentals since 2025-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has fallen from 53.2× (Mar '25) to 15.7× (Sep '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is KMTS growing its revenue and profit?
Over the past 2 years, KESTRA MEDICAL TECHNOLOGIES, LTD.'s revenue has grown 84.9% per year. These are computed facts, not advice.
How much debt does KMTS have?
As of FY2026, KESTRA MEDICAL TECHNOLOGIES, LTD. reported $43M of total debt against $100M of cash; operating income covered interest expense -17.9×.
What is KMTS's profit margin?
In FY2026, gross margin was 51.4%, operating margin -141.6%, and net margin -138.4%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.